Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-83.98M | $-336.00 |
| 2024 | $0.00 | $-56.83M | $-262.00 |
| 2023 | $0.00 | $-31.39M | $-168.00 |
| 2022 | $0.00 | $-51.66M | $-308.00 |
| 2021 | $0.00 | $-89.94M | $-606.00 |
Social Signal Score
Earnings
Wed, Nov 11(in 3 months)
Consensus estimate $-9.95 per share
Typical surprise -21.4% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-12.31 vs $-28.02beat
- Tue, May 12$75.60 vs $-26.00beat
- Mon, Apr 6$-3.50 vs $-3.59beat
- Wed, Nov 12$-50.00 vs $-40.00miss
- Mon, Aug 11$-68.00 vs $-56.00miss
- Tue, May 13$-68.00 vs $-48.00miss
Estimates and results for QNCX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
QNCXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·1d ago·Neutral
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline
View source ↗